Vor Biopharma

Industry · 7 registered clinical trials — 2 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease Primary Sjogren's Disease	Phase 3	2026-02-26
Withdrawn	A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMES Systemic Lupus Erythematosus	Phase 3	2024-09-01
Recruiting	A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) Generalized Myasthenia Gravis	Phase 3	2024-07-17
Terminated	Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogene Leukemia, Myeloid, Acute	Phase 1 / Phase 2	2023-12-11
Terminated	A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMES Systemic Lupus Erythematosus	Phase 3	2022-06-20
Terminated	A Long-term Follow-up Study of Patients Who Received VOR33 Leukemia, Myeloid, Acute	—	2022-04-15
Terminated	Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatmen Leukemia, Myeloid, Acute, Myelodysplastic Syndromes	Phase 1 / Phase 2	2021-12-16